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Abstract
Background & Aims: Controlled Attenuation Parameter (CAP) for steatosis assessment 
has not been validated in compensated advanced chronic liver disease cACLD. We 
primarily aimed at assessing the accuracy of CAP for the diagnosis and quantification of 
steatosis in cACLD. Secondary aim: to assess the validity of non-invasive criteria for 
cACLD according to liver stiffness measurement (LSM).
Methods: This is a single center retrospective study including patients with cACLD 
defined as LSM ≥10 kPa, CAP measurement and liver biopsy (reference standard for 
steatosis and fibrosis) observed in 06/2015-06/2017. Steatosis was graded as S0 (<5%), 
S1 (5-32%), S2 (33-66%) and S3 (>66%). The diagnostic performance of CAP for any 
grade of steatosis and for high-grade steatosis (≥S2) was studied. 
Results:  Among 461 consecutive patients, 111 with LSM-based diagnosis of cACLD 
were included (63% male, median age 55 yrs, median BMI 28.1 Kg/m2, etiology: 32% 
NAFLD/NASH, 32% alcohol or viral +metabolic syndrome, 15% viral, 6% autoimmune, 
4% alcohol, 11% others). Median LSM and CAP were 16.1 kPa and 277 dB/m, 
respectively. On liver biopsy, steatosis was found in 88/111 patients (79%); 44 patients 
(43 with metabolic syndrome) had high-grade steatosis.  
CAP was accurate in identifying any grade of steatosis (AUROC 0.847;95%CI 0.767-
0.926,p<0.0001), and ≥S2 steatosis (0.860;95%CI0.788-0.932,p<0.0001). CAP 
performed similarly in patients with CAP-IQR≥ or <40 dB/m.
Conclusions: Steatosis is frequent in patients with cACLD and metabolic syndrome. 
CAP diagnostic accuracy for any steatosis and high-grade steatosis is good in this 
population. A CAP-IQR ≥40 dB/m does not impair CAP diagnostic accuracy in cACLD. 
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Lay Summary
 Steatosis (fatty liver) is currently frequent in patients with histologically confirmed 
advanced liver fibrosis or cirrhosis, particularly if features of metabolic syndrome 
ar present (obesity, increased arterial blood pressure, diabetes,  increased 
cholesterol and/or triglycerids)
 CAP reflects intrahepatic fat content with good accuracy, and is more useful to 
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INTRODUCTION
Steatosis due to nonalcoholic fatty liver disease (NAFLD) has become one of the most 
frequent causes of referral for chronic liver disease(1) and the progressive form of 
NAFLD (non-alcoholic steato-hepatitis-NASH) is associated with increased risk of 
cirrhosis(2) and hepatocellular carcinoma development, even in non-cirrhotic livers(3). 
Furthermore, steatosis is an important co-factor of progression in chronic liver disease of 
any cause(4, 5). In patients with compensated advanced chronic liver disease (cACLD, 
corresponding to bridging fibrosis or cirrhosis)(6), overweight/obesity- the main 
determinants of an increased liver fat content- predict clinical decompensation 
independent of portal pressure and serum albumin(7). Moreover, in patients with cACLD 
due to chronic Hepatitis C, steatosis was associated with a higher risk of progression to 
cirrhosis or its complications(8). This data underlines the importance of correctly 
diagnosing and quantifying liver fat content in patients with cACLD. However, liver biopsy 
is not routinely performed in patients with cACLD, who are well diagnosed by liver 
stiffness measurement (LSM). Recently, controlled attenuation parameter (CAP) has 
become available(9, 10). This simple, non-invasive technique allows diagnosing and 
quantifying liver fat content simultaneously to LSM using FibroScan®(11). A recent meta-
analysis confirmed that CAP is a reliable method to diagnose significant steatosis(12). On 
the other hand, LSM are higher in patients with higher CAP, and, in turn, patients with 
LSM >10 kPa show higher CAP values even in the absence of severe steatosis, 
suggesting a complex interaction between the two(12)(13, 14). Since severe fibrosis or 
cirrhosis was present in only 20-25% of cases included in previous studies (12, 15), CAP 
has been insufficiently studied in this population. In addition, it is assumed that liver fat 
content spontaneously decreases as liver fibrosis progresses to cirrhosis(16, 17), and 
high grades of steatosis are considered unlikely in cACLD. However, in a study 
performed by our group in patients with cACLD, CAP values ≥ 220 dB/m were associated 
with clinically relevant events (18), but due to the lack of histological data, we could not 
prove that a higher CAP mirrored an increased fat content in this specific population. We 
hypothesized that due to the increased prevalence of obesity, liver steatosis would be 
frequent on histology in a contemporary population of patients with cACLD of any cause, 
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The primary aim of the present study was then to assess the accuracy of CAP for 
diagnosis and quantification of steatosis in patients with cACLD of any cause taking 
histology as a gold standard. Secondary aims were to assess the performance of the 
non-invasive criteria for cACLD suggested by the Baveno VI recommendations based on 
LSM and the reliability of CAP measurement based on CAP interquartile range (IQR) (13) 
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METHODS
This is a single center retrospective study that took place at Hepatology, Inselspital, 
University of Bern, Switzerland. The study was approved by the Ethical Committee of the 
Canton Bern (EK BE 2017-00501).
For the inclusion in this study, presence of cACLD was a mandatory criterion. cACLD 
was defined non-invasively according to the Baveno VI criteria, by LSM ≥10 kPa using 
transient elastography (FibroScan, Echosense, France), irrespective of whether it was 
measured by M or XL probe. 
We reviewed all consecutive patients who underwent a liver biopsy for diagnostic 
assessment or staging of a chronic liver disease of any etiology at our center between 
June 2015 and June 2017. In addition to a LSM ≥10 kPa, a CAP measurement within 6 
months prior to the liver biopsy was required. 
We excluded patients with any previous or ongoing hepatic decompensation (defined as 
ascites, variceal bleeding, hepatic encephalopathy, jaundice), with AST and/or ALT>5 
times ULN(19), those with an invalid LSM measurement (IQR/M>0.30), and those in 
whom the quality of the histological sample was insufficient for a proper interpretation. 
Figure 1 illustrates the selection flow-chart. 
Clinical and laboratory variables were collected at the closest time of liver biopsy (in any 
case within 3 months). Alcohol consumption at the time of biopsy was classified as none, 
mild (<20 g/day for women, and <30 g/day for men) or moderate/severe (Table 1). 
LSM and CAP measurement
After ≥6 hour fast, LSM and CAP were simultaneously measured with FibroScan 502 
Touch (Echosens, Paris, France) using the appropriate probe (M or XL), according to the 
skin-capsule distance. For CAP, attenuation of the transmitted waves was measured 
automatically in the central frequency of the probe and was expressed in dB/m. Only 
patients with valid LSM measurements were included(9, 19), and the final LSM (in kPa) 
and CAP values (in dB/m) were given as the median of 10 valid measurements and IQR.
LSM was further classified in three categories according to the Baveno VI definitions(6): 
LSM 10-15 kPa: suggestive of cACLD; LSM >15 kPa: highly suggestive of cACLD; LSM ≥ 
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The following CAP cut-offs previously published were tested: for any degree of steatosis 
≥ 220 dB/m(18) and ≥ 248 dB/m(12); for S2-S3: ≥ 268 dB/m(12); for S3: ≥ 280 dB/m(12).
Liver histology
Liver biopsies were performed using either percutaneous or transjugular access. Briefly, 
percutaneous liver biopsies were performed with ultrasound assistance, according to 
Menghini’s technique, as previously described(20), using a 17G biopsy needle (Hepafix®, 
Braun, Germany). The technique used for transjugular liver biopsy (TJLB) at our center is 
described in detail elsewhere(21). Samples were fixed in formalin, and were sent to the 
pathology department. Stainings included Hematoxilin-Eosin, Reticulin and Masson’s 
trichrome (chromotrope aniline blue). An expert pathologist scored fibrosis according to 
the METAVIR, Brunt, or Ishak scores, as required by the disease etiology. Fibrosis was 
assessed semiquantitatively, and cirrhosis was defined by the presence of septa and 
nodules. Advanced chronic liver disease (ACLD) on histology was defined as a bridging 
fibrosis or cirrhosis, irrespective of the etiology. Steatosis was graded as S0 (<5%), S1 
(5-32%), S2 (33-66%), S3 (>66%) in relation to the percentage of hepatocytes containing 
fat droplets(22). 
The representativeness of the biopsy was scored using the length of the biopsy specimen 
and the number of portal tracts. A biopsy was considered optimal in the case of a 
specimen of at least 20 mm in length or with at least 15 portal tracts; sufficient when the 
specimen was not 20 mm in length, but had at least 11 portal tracts and suboptimal in the 
remaining cases(23). Patients in whom liver fibrosis could not be staged on histology 
were excluded from the analysis.
Statistical Analysis
Quantitative variables normally distributed were expressed as mean and standard 
deviation, while not-normally distributed variables were shown as median and 
interquartile range. Comparison of CAP values across to steatosis grade was obtained by 
Kruskal-Wallis test. Comparison of quantitative variables between two groups was done 
by using T test or non-parametric tests, according to the normality of the distribution. 
Comparison of proportions was done by Fisher Exact test or Kruskal-Wallis test, as 
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steatosis was studied using the area under the receiving operating characteristic curves 
(AUROC). Sensitivity, Specificity, positive (+LR) and negative likelihood ratios (-LR) and 
accuracy were calculated for previously published and pre-defined CAP cut-offs for 
steatosis(12, 18).
Data were analyzed using SPSS statistics version 23 (SPSS Inc., Chicago, IL, USA).
RESULTS
461 consecutive patients underwent biopsy (transjugular or percutaneous) for liver 
disease at our center in the study period. Among them, 147 patients met the Baveno VI 
definition of cACLD according to LSM. After excluding patients with invalid 
measurements or exceeding the allowed time period between biopsy and LSM, AST 
and/or ALT >5 times ULN (n=13), 111 patients (60% percutaneous biopsy, 40% TJLB) 
were included in the final analysis (Figure 1). 
The characteristics of the included patients are summarized in Table 1. In brief, 63% 
were male, and most were overweight (median BMI 28.1 Kg/m2, 36% obese). More than 
a half of the population had a metabolic syndrome component: in 32% the liver disease 
was due to NAFLD/NASH while an additional 32% had viral or alcohol related liver 
disease and metabolic syndrome as a co-factor. 
As for transient elastography, 71% of patients were studied using M probe, while 29% 
underwent measurements with XL probe. Median LSM was 16.1 kPa (range 10-75). 42% 
of patients had a LSM between 10 and 15 kPa, while 58 % had a LSM ≥15 kPa.  In 34% 
LSM was ≥ 21 kPa. 
Table 2 shows the histological stage of fibrosis according to the result of LSM.  As 
shown, using a cut-off of 10 kPa, the presence of ACLD was overestimated in about 40% 
of patients, while among patients with LSM ≥ 21 kPa 82% had ACLD confirmed on 
histology. As for factors associated with misdiagnosis of cACLD, ongoing alcohol 
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(Supplementary Table 1). Fat content per se or CAP did not explain misclassification of 
fibrosis in this series.
87% of the biopsy samples were large enough to be considered well representative. 
On histology, fibrosis was found in 98/111 (88%), being mild in 11%, moderate in 17%, 
and bridging fibrosis or cirrhosis in 72%.  
CAP and histological steatosis in patients with cACLD diagnosed according to the 
Baveno VI criteria 
In the 111 patients analyzed, the median CAP value was 277 dB/m. Table 1 shows the 
distribution of patients according to the different CAP cut-offs. In 78 patients (70%) CAP 
was ≥ 220 dB/m. 
On liver biopsy, steatosis was found in 88/111 (79%) of patients. 44 patients had a high 
grade steatosis (≥ 33%; ≥S2). 43 out of these 44 cases were patients with NAFLD/NASH 
or with alcoholic or viral disease in combination with metabolic syndrome.  
  
CAP was accurate in identifying steatosis of any grade, with an area under the ROC 
curve (AUROC) of 0.847 (95%, CI 0.767-0.926, p <0.0001) (Figure 2, Panel A). Similar 
good results were found for the detection of S2-S3 steatosis (AUROC 0.860; 95% CI 
0.788-0.932, p <0.0001) (Figure 2, Panel B). 
Results regarding the accuracy of previously published CAP cut-offs for the detection of 
any grade of steatosis and high-grade steatosis are shown in Table 3. 
To detect any degree of steatosis, accuracy was similar for the two studied cut-offs: 
80.2% for the cut-off 220 dB/m (95% CI: 71.5%-87.1%) and 79.3 % for the cut-off 248 
dB/m (95%CI: 70.6%-86.4%). However, the threshold of 220 dB/m showed a higher 
sensitivity as compared to the 248 dB/m cut-off (85 % vs. 79 %). For high-grade (S2-S3) 
steatosis, the cut-off of 268 dB/m showed a very high sensitivity (92.7%) with moderate 
specificity (70%) and acceptable accuracy (78.4%). For S3 steatosis, the 280 dB/m cut-
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CAP and histological steatosis in patients with cACLD confirmed on histology
Bridging fibrosis or cirrhosis (cACLD) were diagnosed on histology in 70/111 patients. 
Within this group, 54 patients (77%) had at least some steatosis, and 27 (39%) had a 
significant or high grade of steatosis (S2-S3). The AUROC of CAP for the diagnosis of 
any grade of steatosis was 0.804 (95% CI 0.683-0.925; p<0.001). For S2-S3 steatosis 
AUROC was 0.828 (95% CI 0.727-0.930; p<0.0001) (Figure 3). In this subgroup of 
patients with histologically confirmed cACLD, the 220 dB/m cut-off resulted in a higher 
sensitivity and in higher accuracy to detect any degree of steatosis as compared to the 
248 dB/m cut-off (Table 3). The 268 dB/m cut-off had a sensitivity >90% and a good 
accuracy (81%) to discriminate between patients with S0-S1 and S2-S3 steatosis. On the 
other hand, the accuracy of the 280 dB/m cut-off to identify patients with S3 steatosis was 
insufficient (61%).
Histologically, a diagnosis of cirrhosis was done in 36 cases (27 with any degree of 
steatosis, of whom 16 had S2-S3 steatosis). The AUROC of CAP to diagnose any 
steatosis was 0.871 (0.789-0.953) in patients without cirrhosis, and 0.780 (0.589-0.970) 
in patients with cirrhosis (p=0.39 vs. no cirrhosis). The best CAP cut-off to identify any 
steatosis in cirrhosis was 219 dB/m (Sensitivity 85%, Specificity 78%).
The AUROC for S2-S3 steatosis was 0.899 (0.824-974) in patients without cirrhosis vs. 
0.794 (0.637-0.951) in patients with cirrhosis (p=0.21 vs. no cirrhosis). The best CAP cut-
off to identify S2-S3 steatosis in cirrhosis was 270 dB/m (Sensitivity 87%, Specificity 
75%).
CAP accuracy for steatosis in patients with and without metabolic syndrome 
As expected, the proportion of any steatosis and S2-S3 steatosis differed between 
patients with and without metabolic syndrome: any steatosis: 98% vs. 41% (p=0.03); S2-
S3 steatosis 59% vs. 11% (p=0.0004). The AUROC of CAP to identify any steatosis in 
patients without metabolic syndrome was good (0.777; 95%CI 0.635-0.919) and for S2-
S3 steatosis, CAP performed similarly in patients with and without metabolic syndrome 
(AUROC 0.790; 95% 0.661-0.919 vs. 0.795; 95% CI 0.582-1.000; comparison of the 
AUROCS: p=0.97). As for S2-S3 steatosis, the best cut-off in patients with metabolic 
syndrome was 303 dB/m (Sens 81%, Spec 72%), while it appeared lower in patients 
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Performance of CAP for steatosis in cACLD according to CAP IQR
The discriminative ability of CAP for any grade of steatosis and for S2-S3 steatosis was 
similar in patients with CAP IQR ≥ or < 40 dB/m. For any grade of steatosis: AUROC 
0.848 (95% CI: 0.732-0.964, p<0.001) with CAP IQR ≥ 40 dB/m vs 0.811 (95% CI: 0.670-
0.951, p=0.01) in patients with CAP IQR <40 dB/m). For S2-S3 steatosis: AUROC 0.917 
(95% CI 0.834- 0.999, p<0.001) for CAP IQR ≥ 40 dB/m vs. 0.809 (95% CI: 0.693-0.923, 
p<0.001) for CAP < 40 dB/m. The results did not change when the analysis was 
restricted to patients with histologically confirmed cACLD (Supplementary Material). 
Discriminative ability of CAP for the detection of any steatosis and high-grade steatosis 
according to M and XL probe 
In the study population, M probe was used in 71% of cases. No major differences in the 
performance of CAP for steatosis were observed in M vs. XL probe measurements. For 
the diagnosis of any grade of steatosis, CAP measured by M probe showed an AUROC 
of 0.795 (95% CI 0.691-0.898; p<0.0001). For S2-S3 steatosis, the AUROC was 0.836 
(95% CI 0.737-0.936; p<0.0001).
Using XL probe, CAP showed an AUROC of 0.958 (95% CI 0.884-1.00; p=0.032) for the 
diagnosis of any grade of steatosis, and of 0.871 (95% CI 0.742-1.00; p<0.0001) for S2-
S3 steatosis.
Restricting the analysis to patients with histologically confirmed cACLD, similar results 
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DISCUSSION
The non-invasive identification and risk stratification of patients with cACLD is 
challenging, but of high importance given that at this stage of the disease the risk of 
developing portal hypertension and hepatocellular carcinoma is markedly increased. 
Steatosis is associated with progression of liver fibrosis and to increased risk of clinical 
decompensation in this population(8). On the other hand, severe steatosis is associated 
with an overestimation of liver fibrosis by transient elastography(13-15). Hence, reliable 
tests mirroring the presence and grade of steatosis are needed for a correct risk 
stratification in the setting of compensated patients assumed or confirmed to have a 
cACLD. 
In the present work, we aimed to assess the reliability of CAP in a contemporary 
population of patients with cACLD of any etiology diagnosed by LSM according to the 
Baveno VI criteria(6), using histology as a gold standard for steatosis.
Contrarily to what was previously assumed(16, 17), here we were able to prove that 
steatosis is nowadays very frequent in patients with histologically confirmed bridging 
fibrosis or cirrhosis, being observed in 77% of the patients. However, not surprisingly, a 
significant or severe liver fat content was almost exclusively observed in patients with 
metabolic syndrome, either as the sole cause of cACLD or as a cofactor added to other 
etiologies. This implies, that given its negative prognostic role in this population, high-
grade steatosis should be clinically suspected and carefully investigated for in patients 
with cACLD and overweight/obesity and/or metabolic risk factors(8).
In this cohort, we have shown that CAP is able to identify any grade of steatosis and S2-
S3 steatosis with good accuracy, with results that do not differ from those obtained in 
patients with less severe chronic liver disease(12). Importantly, the results did not change 
if we restricted the analysis to patients in whom severe fibrosis or cirrhosis was confirmed 
on histology. 
In our population, a CAP IQR of less than 40 dB/m did not further improved CAP 
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As for probe size, CAP measured either with M or XL probe seemed to be similarly for 
steatosis or high-grade steatosis, confirming data recently obtained in Asian patients(24).
Our study is the first analyzing the diagnostic performance of CAP vs. histology in the 
setting of cACLD, and our data support that the cut-off of 268 dB/m(12) is accurate to 
rule-out high-grade steatosis in cACLD. 
In addition, our results validate the cut-off of 220 dB/m, which we previously used and 
that was associated with increased morbidity in patients with cACLD independent of 
LSM(18). This CAP cut-off holds a >80% sensitivity for steatosis detection, performing 
better than that proposed in the recent meta-analysis for this specific aim(12). 
We acknowledge that our study suffers from limitations. It is a retrospective and single 
center study, and it included a relatively low number of individuals; in addition, our 
population showed a high prevalence of NAFLD and metabolic syndrome and the pre-
test probability of steatosis and S2-S3 steatosis was therefore high in our patients.Given 
to that liver biopsy is an imperfect gold-standard and sampling error can lead to under- or 
overestimation of fibrosis(25), we cannot exclude that some of the patients considered as 
misclassified by LSM might instead have cACLD not evident on the biopsy sample. 
Finally, the Baveno criteria for cACLD identification showed a high proportion of false 
positive results in the present series; overestimation of fibrosis was more frequent in 
patients with metabolic syndrome and/or NAFLD/NASH, confirming previous 
data(4)(15)(16), and suggesting caution in the interpretation of LSM in this context. 
Importantly, the results regarding CAP accuracy were confirmed in patients with 
histologically proven bridging fibrosis or cirrhosis.
In conclusion, steatosis was very frequent in a contemporary population of patients with 
histologically confirmed advanced fibrosis or cirrhosis and severe steatosis likelihood is 
high in patients with clinical features of metabolic syndrome, irrespective of the main 
etiology of cACLD. CAP reflected intrahepatic fat content with good accuracy, being 
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Table 1. Clinical characteristics of the included population (n=111).
Age, mean ± SD 55.3 ± 12.7
Male sex, N (%) 70 (63)
Body mass Index (Kg/m2) mean ± SD 28.1 ± 5.5 
Etiology  
NAFLD/NASH, % 32





Laboratory values  
Platelets (G/L), mean ± SD 185 ± 93
Total bilirubin (μmol/l), mean ± SD 19.5 ± 36.7
AST (U/l), mean ± SD 99 ± 34
ALT (U/l), mean ± SD 66 ± 40
Albumin (g/l), mean ± SD 37 ± 10
Glucose (mmol/l)mean ± SD 6.2 ± 2.7
Insulin (mU/l), mean ± SD 19.8 ± 14.5
Total cholesterol (mmol/l), mean ± SD 4.76 ± 1.3
Triglycerides (mmol/l), mean ± SD 1.6 ± 1.06
ALP (U/l), mean ± SD 120 ± 136
GammaGT (U/l), mean ± SD 270 ± 418
Creatinine (μmol/l), mean ± SD 75 ± 32
Transient elastography probe used 
M Probe (%) 71
XL Probe (%) 29
Liver stiffness  
LS: 10-15 kPa, N (%) 47 (42.3)
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LS: ≥ 21 kPa, N (%) 34 (30.6)
CAP
≥ 220 dB/m, N(%) 78 (70.3)
≥248 dB/m, N(%) 69 (62.2)
≥268 dB/m, N(%) 59 (53.2)
≥280 dB/m, N(%) 55 (49.5)
CAP IQR <40, N (%) 69 (62)




Steatosis grade  
S0 (<5%), N (%) 23 (18.5)
S1 (5-32%), N (%) 42 (33.9)
S2 (33-66%), N (%) 24 (19.3)
S3 (>66%), N (%) 20 (16.2)
Fibrosis on LB  
F0-F2, N (%) 41 (36.9)
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No fibrosis or 
mild fibrosis
Significant fibrosis, no 
bridging fibrosis no 
cirrhosis
Bridging fibrosis or 
cirrhosis (cACLD)
LSM 10-15 kPa (cACLD 
likely), n=47
10 (21%) 10 (21%) 27 (58%)
LSM ≥ 15 kPa 
(cACLD very likely), n=64
14 (22%) 7 (11%) 43 (67%)














Table 2. Liver fibrosis severity on histology according to the LSM cut-offs 
proposed by the Baveno VI consensus.
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Complete study population: cACLD diagnosed by LSM
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Figure Legends
Figure 1. Flow-chart of the study population. LS, liver stiffness; CAP, controlled 
attenuation parameter; cACLD, compensated advanced chronic liver disease. 
Figure 2. Discriminative ability of CAP to diagnose steatosis in patients diagnosed 
of cACLD using the Baveno VI criteria (LSM ≥10 kPa). Panel A. CAP for any grade 
of steatosis. AUROC 0.847 (95% CI 0.767-0.926, p<0.0001). Panel B. CAP for S2-S3 
steatosis. AUROC 0.860 (95% CI 0.788-0.932, p<0.0001).
Figure 3. Discriminative ability of CAP for S2-S3 steatosis in patients with 
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